COMMUNIQUÉS West-GlobeNewswire

Renaissance BioScience files PCT Patent Application for Yeast-based RNA Bioactive Molecule Production and Delivery Technology Platform
16/05/2019
VANCOUVER, British Columbia, May 16, 2019 (GLOBE NEWSWIRE) -- Renaissance BioScience Corp., a leading biological engineering company, is pleased to announce the filing on May 8, 2019 of a PCT patent application for a [...]
“CADScor®System will shorten waiting lists and add value for both patients and healthcare system” Dr. Werner Kommer Facharzt für Innere Medizin und Kardiologie in Wolkersdorf, Austria
16/05/2019
Interim Report, January – March 2019 Malmö, May 16, 2019 “CADScor®System will shorten waiting lists and add value for both patients and healthcare system” Dr. Werner Kommer Facharzt für Innere Medizin und Kardiologie in [...]
Biocartis Group NV: Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference
16/05/2019
PRESS RELEASE : 16 May 2019, 07:00 CEST Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]
Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials
16/05/2019
Sym021 a novel anti-PD1 compound currently in Phase 1 clinical trials Copenhagen, 16 May 2019 – Symphogen, a private clinical stage oncology focused biopharmaceutical company with a productive antibody discovery engine [...]
Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting
16/05/2019
REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO [...]
MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
16/05/2019
LA JOLLA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Veritas Announces Restructuring of Cannevert Therapeutics Ltd.
15/05/2019
VANCOUVER, British Columbia, May 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has undertaken steps to restructure and rebuild [...]
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
15/05/2019
Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileucel following failure of checkpoint inhibitors had [...]
CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting
15/05/2019
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody [...]
Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
15/05/2019
SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company discovering and developing optimized biologics for cancer and autoimmune disorders, today announced company researchers [...]
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
15/05/2019
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) Oral abstract will be presented at American Society of [...]
Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting
15/05/2019
BERKELEY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and [...]
Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301
15/05/2019
First healthy volunteer cohort cleared in Phase 1 first-in-human study of BION-1301 for the treatment of IgA nephropathy (IgAN); initial data in healthy volunteers expected in H1 2020 and IgAN patients in H2 2020 [...]
Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting
15/05/2019
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Micron Solutions, Inc. Reports 2019 First Quarter Results
15/05/2019
FITCHBURG, Mich., May 15, 2019 (GLOBE NEWSWIRE) -- Micron Solutions, Inc. (NYSE American: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, [...]
Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
15/05/2019
-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 -- -- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology Therapies, on May 30, 2019 -- MENLO PARK, [...]
Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy
15/05/2019
Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP inhibitors are [...]
Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual Meeting
15/05/2019
SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., a clinical-stage biotechnology company focused on developing potential first-in-class therapeutic candidates for cancers with critical unmet [...]
Y-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting
15/05/2019
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel [...]

Pages